Sacituzumab Govitecan for newly diagnosed TNBC
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with invasive breast cancer that hasn't received any treatment yet.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have adequate blood counts and organ function as shown by lab tests taken during screening.
- You are not pregnant, not breastfeeding, and agree to use highly effective birth control if you could become pregnant or have a partner who could.
- You have no uncontrolled infections, heart problems, or other serious medical conditions.
- You have not had other cancer treatments (like chemotherapy) within the past 3 years, except for certain hormone therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a new drug, Sacituzumab Govitecan, for people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.